Erasca (ERAS) Accounts Payables (2020 - 2026)
Erasca's (ERAS) quarterly Accounts Payables came in at $2.2 million in Q1 2026, down 4.38% YoY from $2.3 million in Q1 2025, and up 120.49% on a QoQ basis from $981000.0 in Q4 2025.
Erasca (ERAS) Accounts Payables (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Accounts Payables data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Accounts Payables fell 4.38% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 4.38% YoY) and the FY2025 annual result came in at $981000.0, up 109.62% from the prior year.
- Accounts Payables improved to $2.2 million in Q1 2026, from $981000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $23.0 million in Q4 2022 to a low of $468000.0 in Q4 2024.
- A 5-year average of $3.8 million and a median of $2.4 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 392.82% — and 2023, when it slumped 91.32%.
- Tracing ERAS's Accounts Payables over 5 years: stood at $23.0 million in 2022, then tumbled by 91.32% to $2.0 million in 2023, then sank by 76.6% to $468000.0 in 2024, then soared by 109.62% to $981000.0 in 2025, then jumped by 120.49% to $2.2 million in 2026.
- The last three Accounts Payables figures came in at $2.2 million (Q1 2026), $981000.0 (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 2.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.02 Mn |
| Mar 31, 2026 | 2.16 Mn |
| Dec 31, 2025 | 981,000.00 |
| Sep 30, 2025 | 3.03 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 468,000.00 |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 3.70 Mn |
| Jun 30, 2023 | 2.63 Mn |
| Mar 31, 2023 | 3.35 Mn |
| Dec 31, 2022 | 23.05 Mn |
| Sep 30, 2022 | 4.32 Mn |
| Jun 30, 2022 | 2.29 Mn |
| Mar 31, 2022 | 4.71 Mn |
| Dec 31, 2021 | 4.68 Mn |
| Sep 30, 2021 | 1.32 Mn |